within Pharmacolibrary.Drugs.ATC.P;

model P02CA51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 4.9999999999999996e-06,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00038333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P02CA51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Mebendazole, in combination with other agents, is an anthelmintic drug used to treat various parasitic worm infestations, such as those caused by roundworms, whipworms, hookworms, and others. Combination products may be used to broaden the spectrum of treatment or enhance efficacy. Mebendazole is generally approved for human use for parasite infections, though combinations may not be available or approved in all regions.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults receiving an oral combination containing mebendazole, based on known parameters for mebendazole monotherapy as no specific data for combinations is available.</p><h4>References</h4><ol><li><p>Cowan, N, et al., &amp; Keiser, J (2016). In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis. <i>Antimicrobial agents and chemotherapy</i> 60(10) 6127–6133. DOI:<a href=\"https://doi.org/10.1128/AAC.01217-16\">10.1128/AAC.01217-16</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27480864/\">https://pubmed.ncbi.nlm.nih.gov/27480864</a></p></li><li><p>Corti, N, et al., &amp; Pauli-Magnus, C (2009). Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. <i>European journal of clinical pharmacology</i> 65(10) 999–1006. DOI:<a href=\"https://doi.org/10.1007/s00228-009-0683-y\">10.1007/s00228-009-0683-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19562329/\">https://pubmed.ncbi.nlm.nih.gov/19562329</a></p></li><li><p>Becelaere, J, et al., &amp; De Clerck, K (2022). Stable amorphous solid dispersion of flubendazole with high loading via electrospinning. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 351 123–136. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2022.09.028\">10.1016/j.jconrel.2022.09.028</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36122898/\">https://pubmed.ncbi.nlm.nih.gov/36122898</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P02CA51;
